Kamel Abou Hussein: Important Milestone in the Evolving Treatment Landscape of HR+/HER2− MBC
Kamel Abou Hussein/LinkedIn

Kamel Abou Hussein: Important Milestone in the Evolving Treatment Landscape of HR+/HER2− MBC

Kamel Abou Hussein, Director of Breast Medical Oncology at MD Anderson Cancer Center at Cooper, shared on LinkedIn:

“The FDA has approved giredestrant (Wilserdly) in combination with everolimus (Afinitor) for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence during or after adjuvant endocrine therapy, or progression on at least one endocrine-based regimen in the metastatic setting.

This approval, based on the Phase III evERA Breast Cancer trial, represents an important advancement in the management of endocrine-resistant breast cancer.

Two complementary therapeutic strategies

  • Giredestrant: an oral selective estrogen receptor degrader (SERD) targeting ER signaling.
  • Everolimus: an mTOR inhibitor targeting an important pathway implicated in endocrine resistance.

The evERA trial demonstrated a meaningful progression-free survival benefit, reinforcing the importance of targeting both estrogen receptor signaling and the PI3K/AKT/mTOR pathway in this setting.

Several important takeaways for clinical practice

  • ESR1 mutation testing is increasingly central to therapeutic decision-making in ER-positive metastatic breast cancer.
  • Endocrine resistance is biologically complex and often requires strategies that address multiple signaling pathways.
  • The expanding role of oral SERDs and rational targeted combinations continues to reshape treatment sequencing following CDK4/6 inhibitor-based therapy.

As our understanding of tumor evolution and acquired endocrine resistance continues to advance, biomarker-driven treatment selection is becoming increasingly important in delivering individualized care.

Another meaningful step forward for patients living with ER-positive metastatic breast cancer.”

You can also read: